Table 2.
Risk of suicidal ideation or self-injury among new users of GLP-1RA vs SGLT-2i
| Person-years | Crude outcomes | Crude rate/1000 person-years | Weighted outcomes | Weighted rate/1000 person-years (95% CI) | HR (95% CI) | ||
|---|---|---|---|---|---|---|---|
| Main analysis | SGLT-2i | 12,575.93 | 17 | 1.35 | 18.11 | 1.44 (0.88, 2.52) | Ref. |
| GLP-1RA | 3785.42 | 10 | 2.64 | 6.66 | 1.76 (0.88, 4.09) | 1.04 (0.35, 3.14) | |
| Intention-to-treat analysis | SGLT-2i | 31,823.39 | 17 | 0.53 | 18.11 | 0.57 (0.35, 1.00) | Ref. |
| GLP-1RA | 7562.30 | 10 | 1.32 | 6.66 | 0.88 (0.44, 2.05) | 1.36 (0.51, 3.61) | |
| Analysis excluding patients with BMI missing data | SGLT-2i | 9966.08 | 13 | 1.30 | 14.76 | 1.48 (0.83, 2.93) | Ref. |
| GLP-1RA | 2714.90 | 7 | 2.58 | 4.54 | 1.67 (0.71, 4.95) | 0.89 (0.26, 3.14) | |
| Analysis with multiple imputation for BMI missing data | SGLT-2i | 12,575.93 | 17 | 1.35 | 18.11 | 1.44 (0.88, 2.52) | Ref. |
| GLP-1RA | 3785.42 | 10 | 2.64 | 6.66 | 1.76 (0.88, 4.09) | 1.29 (0.42, 3.92) |
Ref., reference